Treating Cancer and Collagen-Associated Diseases by Using Anti-LOXL-2 Antibody

  • Yeda
  • From Israel
  • Responsive
  • Patents for licensing

Summary of the technology

An innovative method for treating diseases associated with dysregulation of collagen fibers in the extracellular matrix (ECM), such as cancer and fibrosis, by targeting LOXL-2.


Background and Unmet Need

ECM disruption is associated with many pathological conditions, such as various cancer types and tissue fibrosis, and also correlates with high tumor malignancy. Therefore, controlling ECM composition and morphology is considered a potential treatment for cancer and other ECM-associated diseases, such as liver fibrosis. Presently, there is no therapeutic agent which can manipulate ECM properties for such types of diseases, and therefore a pressing need exists for ECM-modulating agents for the treatment of collagen-associated pathologies.

The Solution

The team led by Prof. Irit Sagi has developed a monoclonal antibody (mAb) which can be targeted against the enzyme lysyl-oxidase like 2 (LOXL-2) - a major ECM regulatory enzyme that modulates collagen structure. LOXL-2 is known to be expressed in numerous cancer types, and has been shown to be associated with enhanced cancer progression and metastasis. Likewise, LOXL-2 inhibition is associated with reduced metastasis and improved clinical outcome. Subsequently, this new anti-LOXL-2 mAb could provide a useful tool to treat cancer development, and possibly other ECM-related pathologies.

Technology Essence

The Sagi group initially screened for an anti-LOXL-2 mAb that would differ from previous anti-LOXL-2 mAb iterations that bind far away from the active site. The Sagi mAb targets the active site of the LOXL-2 enzyme and subsequently leads to a modified ECM. The team discovered that one of the clones, GS341, interrupted the uniform alignment of collagen fibers in the ECM without effecting its composition.
LOXL-2 is expressed not only by resident ECM-inducing cells but also by aggressive malignant cells. Therefore, the Sagi group used MDA-MB-231 - the LOXL-2-expression triple-negative (TNBC) breast cancer cell line - to test the effect of an altered ECM structure on the cancer cell line behavior. They found that inhibition of the LOXL-2 enzyme and subsequent loss of collagen cross-linking led to a disruption of ECM topography. Consequently, MDAMB-231 cells had modified adhesion, morphology, and migration on the altered ECM. In addition, the invasion of cancer cells into the commercial collagen-based matrix was significantly reduced as a result of GS341 treatment.
Following these results which implicated that LOXL-2 targeting can impede cancer development, the team further tested their LOXL-2 mAb in vivo. MDA-MB-231 cells were injected into the mammary fat pads of immunocompromised SCID mice. After 3 weeks of tumor establishment the mice were injected with GS341 for 4 weeks. This treatment, as shown in the figure below, resulted in decreased tumor size (A) and lung metastasis, reduced proliferation (B) and increased tumor fragility (C). These effects also correlated with the disorientation of the fibrils within the tumor as was shown in vitro. These results suggest that LOXL-2 inhibition indeed alters ECM structure and inhibits several aspects of cancer development.
Figure 1: LOXL-2 mAb inhibits tumor growth in vivo. A) Volume quantification of tumors from mice treated with vehicle or GS341 (30 mg/kg, 2 times per week). B) Immunofluorescence staining of tumor sections. DAPI stains (Blue) cell nuclei and phosphohistone3 staining (Green) indicates cell-cycle progression. 3 mice per group, number of cells quantified at least n=10. C) Staining of hematoxylin and eosin (H&E), indicating the structure of tumor scaffold, and Sirius Red, a marker for collagen cross-linking. (Image modified from Grossman M. et al).

Applications and Advantages

  • Inhibiting growth and development of various cancers, including triple negative breast cancer.
  • Possible treatment for other ECM-related pathologies, such as fibrosis and other collagen-associated diseases.
  • Flexible – Can be used as a complementary treatment for conventional therapeutic methods.

Development Status

The group of Prof. Sagi tested the anti-LOXL-2 antibody both in vitro and in vivo. The in vitro work showed that the GS341 antibody interfered with collagen cross-linking in the ECM, resulting in a reduction in tumor cell proliferation, migration, and invasion. The beneficial effects of LOXL-2 inhibition on cancer progression was also demonstrated in vivo, as mice xeno-grafted with triple-negative breast cancer and treated with anti-LOXL-2 exhibited disrupted tumorigenic collagen structure, which correlated with reduced tumor growth. The Sagi group has also shown results in mouse models injected with CCl4 to simulate liver fibrosis. By administering their anti-LOXL-2 mAb they were able to attenuate fibrosis and stimulate the regeneration of tissue.


Grossman, M. et al. ‘Tumor Cell Invasion Can Be Blocked by Modulators of Collagen Fibril Alignment That Control Assembly of the Extracellular Matrix’, Cancer Res 2016 Jul 15;76(14):4249-58. doi: 10.1158/0008-5472

Intellectual property status

  • Granted Patent
  • Patent application number :USA Granted: 10,040,868

Related Keywords

  • Biological Sciences
  • Medicine, Human Health
  • Medical Research
  • Biology / Biotechnology
  • Cellular and Molecular Biology Technology
  • Health care
  • Pharmaceuticals/fine chemicals

About Yeda

Yeda ("Knowledge" in Hebrew) Research and Development Company Ltd. is the commercial arm of the Weizmann Institute of Science (WIS) and is the second company of its kind established in the world.

WIS is one of the world’s leading multidisciplinary basic research institutions in the natural and exact sciences. It is located in Rehovot, Israel, just south of Tel Aviv. It was initially established as the Daniel Sieff Institute in 1934, by Israel and Rebecca Sieff of London in memory of their son Daniel. In 1949, it was renamed for Dr. Chaim Weizmann, the first President of the State of Israel and Founder of the Institute.

Yeda initiates and promotes the transfer to the global marketplace of research findings and innovative technologies developed by WIS scientists. Yeda holds an exclusive agreement with WIS to market and commercialize its intellectual property and generate income to support further research and education.

Since 1959 Yeda has generated the highest income per researcher compared to any other TTO worldwide. Weizmann has generated a number of groundbreaking therapies, such as Copaxone, Rebif, Tookad, Erbitux, Vectibix, Protrazza, Humira, and recently the CAR-T cancer therapy Yescarta.

Yeda performs the following activities:

◣ Identifies and assesses research projects with commercial potential.
◣ Protects the intellectual property of WIS and its scientists.
◣ Licenses WIS' inventions and technologies to industry.
◣ Establishes new Startup companies based in WIS Intellectual Property
◣ Channels funding from industry to research projects.

Our portfolio covers a broad spectrum of the natural sciences, including:

◣ Agriculture and Plant Genetics, including Bio-fuels
◣ Chemistry and Nanotechnology
◣ Environmental Sciences and Solar Energy
◣ Mathematics and Computer Science
◣ Medical Devices
◣ Pharmaceuticals and Diagnostics
◣ Physics and Electro-Optics
◣ Research Tools


Never miss an update from Yeda

Create your free account to connect with Yeda and thousands of other innovative organizations and professionals worldwide


Send a request for information
to Yeda

About Technology Offers

Technology Offers on Innoget are directly posted
and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.


Need help requesting additional information or have questions regarding this Technology Offer?
Contact Innoget support